Giovanna Sarno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Giovanna Sarno has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Stefan James
Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden
6 shared publications Bo Lagerqvist
Department of Medical sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden
5 shared publicationsStefan James
Department of Medical Sciences Uppsala University Uppsala Sweden
4 shared publications- Christoph Varenhorst
Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden
3 shared publications - Daniel Lindholm
Department of Medical Sciences, Uppsala University , Uppsala
3 shared publications Nils Witt
Department of Clinical Science and Education, Karolinska Institutet, Unit of Cardiology, Södersjukhuset, Stockholm, Sweden
3 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by Springer Nature in Clinical Research in Cardiology
- p. 1-10
Prognostic value of risk factors for ischaemic and major bleeding events in chronic coronary syndrome: a SWEDEHEART registry study
Aim: In patients with chronic coronary syndrome, risk factors for ischaemic events and bleeding tend to overlap. However, the combined effects of these factors have scarcely been studied in contemporary real-world settings. Methods: All patients in Sweden undergoing elective PCI for chronic coronary syndrome between 2006 and 2014 enrolled in the SWEDEHEART registry were included. Six risk factors (age ≥ 65 years, chronic kidney disease, diabetes, multivessel disease (MVD), prior bleeding, and prior acute myocardial infarction (AMI)) were assessed in relation to the risk of ischaemic (cardiovascular death/AMI/stroke) and major bleeding events. Results: We studied 24,051 patients, of whom 59% had ≥ 2 risk factors. During a median follow-up of 3.7 years, 3604 (15.0%) patients experienced ischaemic events and 2076 (8.6%) experienced major bleeding events . Higher numbers of risk factors were associated with a stepwise increase in the incidence of both ischaemic and bleeding events, being more substantial for ischaemic compared to bleeding events. In adjusted Cox models, prior bleeding was of less importance as compared to other risk factors for new ischaemic events. For bleeding events, diabetes, MVD, and prior AMI had limited relevance compared with other risk factors. When excluding patients with prior major bleeding, the increase in ischaemic risk with an increasing number of risk factors was more pronounced, whereas the increase in bleeding incidence was attenuated. . Conclusions: Among patients with angiographically confirmed chronic coronary syndrome, the majority had two or more established risk factors. An increasing number of risk factors was associated with a higher rate of ischaemic and bleeding events, being more substantial for ischaemic compared to bleeding events.
- 10 August 2026
- Published by Springer Nature in Clinical Research in Cardiology
- p. 1-10
Open AccessPrognostic value of risk factors for ischaemic and major bleeding events in chronic coronary syndrome: a SWEDEHEART registry study
Aim: In patients with chronic coronary syndrome, risk factors for ischaemic events and bleeding tend to overlap. However, the combined effects of these factors have scarcely been studied in contemporary real-world settings. Methods: All patients in Sweden undergoing elective PCI for chronic coronary syndrome between 2006 and 2014 enrolled in the SWEDEHEART registry were included. Six risk factors (age ≥ 65 years, chronic kidney disease, diabetes, multivessel disease (MVD), prior bleeding, and prior acute myocardial infarction (AMI)) were assessed in relation to the risk of ischaemic (cardiovascular death/AMI/stroke) and major bleeding events. Results: We studied 24,051 patients, of whom 59% had ≥ 2 risk factors. During a median follow-up of 3.7 years, 3604 (15.0%) patients experienced ischaemic events and 2076 (8.6%) experienced major bleeding events . Higher numbers of risk factors were associated with a stepwise increase in the incidence of both ischaemic and bleeding events, being more substantial for ischaemic compared to bleeding events. In adjusted Cox models, prior bleeding was of less importance as compared to other risk factors for new ischaemic events. For bleeding events, diabetes, MVD, and prior AMI had limited relevance compared with other risk factors. When excluding patients with prior major bleeding, the increase in ischaemic risk with an increasing number of risk factors was more pronounced, whereas the increase in bleeding incidence was attenuated. . Conclusions: Among patients with angiographically confirmed chronic coronary syndrome, the majority had two or more established risk factors. An increasing number of risk factors was associated with a higher rate of ischaemic and bleeding events, being more substantial for ischaemic compared to bleeding events.
- Open Access
- 28 February 2025
- Published by Uppsala Medical Society in Upsala Journal of Medical Sciences
- Vol. 130, e10999
Transcatheter aortic valve implantation in Uppsala University Hospital 2009–2023: outcomes and temporal trends
Background: In recent years, transcatheter aortic valve implantation (TAVI) has rapidly emerged as a key treatment option for aortic stenosis. TAVI has been performed at Uppsala University Hospital since 2009. Data on TAVI procedures have been collected in a nation-wide all-comer registry, the Swedish Transcatheter Cardiac Intervention Registry (SWENTRY). However, only limited analysis has been conducted on trends in short- and long-term outcomes of TAVI patients in Sweden. Methods: This registry-based cohort study aims to evaluate outcome trends and long-term prognosis in patients who underwent TAVI in a Swedish single center between 2009 and 2023. Survival outcomes were studied using the Kaplan–Meier method. Cox Proportional Hazards models were used to adjust for differences in patient characteristics over time. Results: In total, 1,741 TAVI procedures were performed between 2009 and 2023. Immediate procedural mortality and 1-year mortality averaged at 0.9 and 8.1%, respectively. Both procedural and long-term mortality showed a decreasing trend over time. Similar results were observed when controlling for comorbidities and age. Conclusions: Short-term outcomes and long-term prognosis have been constantly improving for patients undergoing TAVI within this study. Similar mortality and complication trends have been observed in other registry studies. These trends may be attributed to improvements in the quality of care, and the increased use of TAVI in lower risk patients.
- 28 February 2025
- Published by Uppsala Medical Society in Upsala Journal of Medical Sciences
- Vol. 130, e10999
Open AccessTranscatheter aortic valve implantation in Uppsala University Hospital 2009–2023: outcomes and temporal trends
Background: In recent years, transcatheter aortic valve implantation (TAVI) has rapidly emerged as a key treatment option for aortic stenosis. TAVI has been performed at Uppsala University Hospital since 2009. Data on TAVI procedures have been collected in a nation-wide all-comer registry, the Swedish Transcatheter Cardiac Intervention Registry (SWENTRY). However, only limited analysis has been conducted on trends in short- and long-term outcomes of TAVI patients in Sweden. Methods: This registry-based cohort study aims to evaluate outcome trends and long-term prognosis in patients who underwent TAVI in a Swedish single center between 2009 and 2023. Survival outcomes were studied using the Kaplan–Meier method. Cox Proportional Hazards models were used to adjust for differences in patient characteristics over time. Results: In total, 1,741 TAVI procedures were performed between 2009 and 2023. Immediate procedural mortality and 1-year mortality averaged at 0.9 and 8.1%, respectively. Both procedural and long-term mortality showed a decreasing trend over time. Similar results were observed when controlling for comorbidities and age. Conclusions: Short-term outcomes and long-term prognosis have been constantly improving for patients undergoing TAVI within this study. Similar mortality and complication trends have been observed in other registry studies. These trends may be attributed to improvements in the quality of care, and the increased use of TAVI in lower risk patients.
- Open Access
- 15 October 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (20) , e035448
Major Adverse Cardiovascular Events Following Coronary Artery Stenting by History of Hypertensive Disorder of Pregnancy
Background: A history of hypertensive disorders of pregnancy is associated with at least twice the risk of incident ischemic heart disease. Whether the long‐term outcome following treatment with coronary artery stenting is associated to the history of hypertensive disorders of pregnancy is unknown. Methods and Results: We included 8364 women (age ≤65 years) undergoing first coronary artery stenting 2006 to 2022 following their first delivery in 1973 or later, linking nationwide data on percutaneous coronary intervention and delivery history. In total, 1122 women (13.4%) had a history of hypertensive disorders of pregnancy. The main outcome, a major adverse cardiovascular event, was defined as any incident myocardial infarction, ischemic heart disease, cardiac arrest, arrhythmias, angina pectoris, heart failure, cerebral infarction, or sudden death. During a median follow‐up time of 5 years, 258 women with a history of hypertensive disorders of pregnancy had a major adverse cardiovascular event, compared with 1465 women without a history of hypertensive disorders of pregnancy (23% versus 20.2%, P =0.028 for log‐rank test). Estimates adjusted for patient‐ and procedural characteristics in proportional hazards regression models suggested that the hazard rate increased only after 4–8 years of follow‐up (hazard ratio [HR], 1.36 [95% CI, 1.05–1.78]) and was primarily driven by women with history of gestational hypertension (HR, 2.15 [95% CI, 1.49–3.11]). Conclusions: Women with a history of hypertensive disorders of pregnancy have an increased risk of a major adverse cardiovascular event following coronary artery stenting compared with other parous women. A history of hypertensive disorders of pregnancy warrants further attention in the secondary prevention setting of coronary artery disease.
- 15 October 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (20) , e035448
Open AccessMajor Adverse Cardiovascular Events Following Coronary Artery Stenting by History of Hypertensive Disorder of Pregnancy
Background: A history of hypertensive disorders of pregnancy is associated with at least twice the risk of incident ischemic heart disease. Whether the long‐term outcome following treatment with coronary artery stenting is associated to the history of hypertensive disorders of pregnancy is unknown. Methods and Results: We included 8364 women (age ≤65 years) undergoing first coronary artery stenting 2006 to 2022 following their first delivery in 1973 or later, linking nationwide data on percutaneous coronary intervention and delivery history. In total, 1122 women (13.4%) had a history of hypertensive disorders of pregnancy. The main outcome, a major adverse cardiovascular event, was defined as any incident myocardial infarction, ischemic heart disease, cardiac arrest, arrhythmias, angina pectoris, heart failure, cerebral infarction, or sudden death. During a median follow‐up time of 5 years, 258 women with a history of hypertensive disorders of pregnancy had a major adverse cardiovascular event, compared with 1465 women without a history of hypertensive disorders of pregnancy (23% versus 20.2%, P =0.028 for log‐rank test). Estimates adjusted for patient‐ and procedural characteristics in proportional hazards regression models suggested that the hazard rate increased only after 4–8 years of follow‐up (hazard ratio [HR], 1.36 [95% CI, 1.05–1.78]) and was primarily driven by women with history of gestational hypertension (HR, 2.15 [95% CI, 1.49–3.11]). Conclusions: Women with a history of hypertensive disorders of pregnancy have an increased risk of a major adverse cardiovascular event following coronary artery stenting compared with other parous women. A history of hypertensive disorders of pregnancy warrants further attention in the secondary prevention setting of coronary artery disease.
- 23 October 2023
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 102 (7) , 1408-1409
External validation of the Netherlands Heart Registration (NHR) prediction model for early mortality after transcatheter aortic valve implantation (TAVI)
- 23 October 2023
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 102 (7) , 1408-1409
External validation of the Netherlands Heart Registration (NHR) prediction model for early mortality after transcatheter aortic valve implantation (TAVI)
- 1 June 2020
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 13 (11) , 1380-1381
Reply
- 1 June 2020
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 13 (11) , 1380-1381
Reply
- 1 April 2020
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 13 (7) , 793-804
Percutaneous Treatment and Outcomes of Small Coronary Vessels
- 1 April 2020
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 13 (7) , 793-804
Percutaneous Treatment and Outcomes of Small Coronary Vessels
- Open Access
Combined association of key risk factors on ischaemic outcomes and bleeding in patients with myocardial infarction
Objective In patients with myocardial infarction (MI), risk factors for bleeding and ischaemic events tend to overlap, but the combined effects of these factors have scarcely been studied in contemporary real-world settings. We aimed to assess the combined associations of established risk factors using nationwide registries. Methods Using the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies registry, patients with invasively managed MI in 2006–2014 were included. Six factors were assessed in relation to cardiovascular death (CVD)/MI/stroke, and major bleeding: age ≥65, chronic kidney disease, diabetes, multivessel disease, prior bleeding and prior MI. Results We studied 100 879 patients, of whom 20 831 (20.6%) experienced CVD/MI/stroke and 5939 (5.9%) major bleeding, during 3.6 years median follow-up. In adjusted Cox models, all factors were associated with CVD/MI/stroke, and all but prior MI were associated with major bleeding. The majority (53.5%) had ≥2 risk factors. With each added risk factor, there was a marked but gradual increase in incidence of the CVD/MI/stroke. This was seen also for major bleeding, but to a lesser extent, largely driven by prior bleeding as the strongest risk factor. Conclusions The majority of patients with MI had two or more established risk factors. Increasing number of risk factors was associated with higher rate of ischaemic events. When excluding patients with prior major bleeding, bleeding incidence rate increased only minimally with increasing number of risk factors. The high ischaemic risk in those with multiple risk factors highlights an unmet need for additional preventive measures.
Open AccessCombined association of key risk factors on ischaemic outcomes and bleeding in patients with myocardial infarction
Objective In patients with myocardial infarction (MI), risk factors for bleeding and ischaemic events tend to overlap, but the combined effects of these factors have scarcely been studied in contemporary real-world settings. We aimed to assess the combined associations of established risk factors using nationwide registries. Methods Using the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies registry, patients with invasively managed MI in 2006–2014 were included. Six factors were assessed in relation to cardiovascular death (CVD)/MI/stroke, and major bleeding: age ≥65, chronic kidney disease, diabetes, multivessel disease, prior bleeding and prior MI. Results We studied 100 879 patients, of whom 20 831 (20.6%) experienced CVD/MI/stroke and 5939 (5.9%) major bleeding, during 3.6 years median follow-up. In adjusted Cox models, all factors were associated with CVD/MI/stroke, and all but prior MI were associated with major bleeding. The majority (53.5%) had ≥2 risk factors. With each added risk factor, there was a marked but gradual increase in incidence of the CVD/MI/stroke. This was seen also for major bleeding, but to a lesser extent, largely driven by prior bleeding as the strongest risk factor. Conclusions The majority of patients with MI had two or more established risk factors. Increasing number of risk factors was associated with higher rate of ischaemic events. When excluding patients with prior major bleeding, bleeding incidence rate increased only minimally with increasing number of risk factors. The high ischaemic risk in those with multiple risk factors highlights an unmet need for additional preventive measures.
- 22 May 2017
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 90 (6) , 881-887
Real‐life clinical outcomes with everolimus eluting platinum chromium stent with an abluminal biodegradable polymer in patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
Background: No previous studies have evaluated the performance of the Synergy stent in a large real‐life population.Objectives: To describe the initial real‐life experience with a novel everolimus eluting platinum chromium stent with abluminal biodegradable polymer (SYNERGY) in unselected patients from a nationwide registry.Methods: All implanted Synergy stents were compared with other new generation drug eluting stents (n‐DES) with >1,000 implantations in Sweden between March 2013 and October 2015. Restenosis, definite stent thrombosis (ST), myocardial infarction (MI) and death rates were assessed using propensity score and Cox regression analyses.Results: A total of 7,886 of Synergy stents and 64,429 other n‐DES (BioMatrix, N = 1,953; Orsiro, N = 4,946; Promus Element Plus, N= 2,543; Promus Premier, N= 20,414; Xience Xpedition, N= 7,971, Resolute/Resolute Integrity, N = 19,021; Ultimaster, N = 1,156; Resolute Onyx, N = 6,425) were implanted in 42,357 procedures.Restenosis and stent thrombosis occurred in 642 and 314 cases, respectively, in the overall population at 1 year. The cumulative rate of restenosis (1.1% vs. 1.0%, adjusted HR: 1.24 95% CI: 0.88–1.75; P = 0.21) and ST (0.4% vs. 0.5%, adjusted HR: 0.97; 95% CI: 0.63–1.50; P = 0.17) up to 1 year was low in both the Synergy group and the other n‐DES group. Death occurred in 5.2% versus 4.5% (adjusted HR: 1.14; 95% CI: 0.96–1.36; P = 0.11) and MI in 3.2% versus 3.5%, (adjusted HR: 1.11; 95% CI: 0.93–1.33; P = 0.24) up to 1 year.Conclusions: In a large real‐life population the Synergy stent appears to be safe and effective with a low rate of restenosis and ST comparable with other n‐DES.
- 22 May 2017
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 90 (6) , 881-887
Real‐life clinical outcomes with everolimus eluting platinum chromium stent with an abluminal biodegradable polymer in patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
Background: No previous studies have evaluated the performance of the Synergy stent in a large real‐life population.Objectives: To describe the initial real‐life experience with a novel everolimus eluting platinum chromium stent with abluminal biodegradable polymer (SYNERGY) in unselected patients from a nationwide registry.Methods: All implanted Synergy stents were compared with other new generation drug eluting stents (n‐DES) with >1,000 implantations in Sweden between March 2013 and October 2015. Restenosis, definite stent thrombosis (ST), myocardial infarction (MI) and death rates were assessed using propensity score and Cox regression analyses.Results: A total of 7,886 of Synergy stents and 64,429 other n‐DES (BioMatrix, N = 1,953; Orsiro, N = 4,946; Promus Element Plus, N= 2,543; Promus Premier, N= 20,414; Xience Xpedition, N= 7,971, Resolute/Resolute Integrity, N = 19,021; Ultimaster, N = 1,156; Resolute Onyx, N = 6,425) were implanted in 42,357 procedures.Restenosis and stent thrombosis occurred in 642 and 314 cases, respectively, in the overall population at 1 year. The cumulative rate of restenosis (1.1% vs. 1.0%, adjusted HR: 1.24 95% CI: 0.88–1.75; P = 0.21) and ST (0.4% vs. 0.5%, adjusted HR: 0.97; 95% CI: 0.63–1.50; P = 0.17) up to 1 year was low in both the Synergy group and the other n‐DES group. Death occurred in 5.2% versus 4.5% (adjusted HR: 1.14; 95% CI: 0.96–1.36; P = 0.11) and MI in 3.2% versus 3.5%, (adjusted HR: 1.11; 95% CI: 0.93–1.33; P = 0.24) up to 1 year.Conclusions: In a large real‐life population the Synergy stent appears to be safe and effective with a low rate of restenosis and ST comparable with other n‐DES.